HOWL
Werewolf Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.99
−10.35%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$1.09
From 52W high−29.56%
Volume422175.00
Market cap$47.93M
P/E (TTM)—
P/S (TTM)2.3x
Div yield—
Key dataOct 30, 2026
Open
$1.09
From 52W high
−29.56%
Volume
422175.00
Market cap
$47.93M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.2x
P/E (TTM)
—
RSI (14)
55.6
MomentumView details →
1D Return
−10.35%
YTD Return
+61.80%
SummaryUpdated Jun 1, 2026
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Cambridge, Massachusetts. The company went public in April 2021 and focuses on developing innovative cancer immunotherapies using its proprietary PREDATOR platform technology. Werewolf specializes in creating conditionally activated immune-stimulating molecules designed to overcome the limitations of traditional cancer treatments by precisely targeting tumor environments while minimizing systemic toxicity.
Similar companies
Latest newsMore news →
Werewolf Therapeutics and Ambros Therapeutics announced an oversubscribed $150 million private placement in connection with their merger agreement.71d agoWerewolf Therapeutics and Ambros Therapeutics announced a definitive all-stock merger agreement to combine the companies, with the combined company to operate as Ambros Therapeutics and focus on neridronate for CRPS-1.71d agoWerewolf Therapeutics reported Q2 2026 financial results with revenue of $21.0 million and net income of $3.7 million, compared to a net loss of $18.0 million in Q2 2025.92d ago